Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

ExpreS2ion Biotechnologies - Presentation of Q4 2024 report (Recording)

By Michael FriisHead of Equities
ExpreS2ion Biotech Holding

Today, ExpreS2ion Biotechnologies’ CFO Keith Alexander presented the results and update on business for the fourth quarter of 2024. Furthermore, they gave some insight into the business case around the Breast cancer candidate currently commencing  phase 1.

Watch the recording here:

https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q4-2024

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 11:30, 06-02-2025.

ExpreS2ion Biotech Holding

29.8SEK05.02.2025, 18.00

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Read more on company page

Forum discussions

Biotekdirektør smager egen medicin: Deltager i klinisk forsøg med coronavaccine Adm. direktør Bent U. Frandsen fra biotekselskabet Expres2ion...
12/8/2022, 9:20 AM
by Olivier A. de Goeij
0
ExpreS2ion Biotechnologies offentliggjorde i morges deres tal for deres Q3 rapport, hvor de i den forbindelse afholdte en præsentation af netop...
11/17/2022, 3:20 PM
by Asbjorn Scheller
0
Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk: ExpreS2ion er en biotekvirksomhed med base i Danmark...
10/17/2022, 8:07 AM
by Olivier A. de Goeij
0
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team